Anti-Bribery Probes Sweep China Pharma Third Quarter Earnings
This article was originally published in PharmAsia News
Executive Summary
Vice president of China Pharmaceutical Enterprise Management Association Niu Zhengqian said that China’s nationwide anti-bribery investigations have impacted pharma companies in the third quarter, but companies are expected to recover after the fourth quarter.